09 October 2018
: Case report
Paradoxical Bronchoconstriction with Short-Acting Beta Agonist
Unusual clinical course, Unusual or unexpected effect of treatment, Unexpected drug reaction
Jared S. Magee1BCDEF*, Luke M. Pittman1DEF, Leslie A. Jette-Kelly2BCDDOI: 10.12659/AJCR.910888
Am J Case Rep 2018; 19:1204-1207
Abstract
BACKGROUND: Asthma is a common disease in the U.S. population. Initial therapy in the stepwise approach for asthma management is short-acting β₂-agonist (SABA) therapy as needed for symptom control. However, a significant adverse event that can occur with administration is bronchospasm. Here, we report a case of paradoxical bronchospasm with administration of SABAs during multiple pulmonary function tests (PFTs).
CASE REPORT: A 25-year-old, non-smoking, African American male with a history of moderate asthma and allergic rhinitis treated with fluticasone/salmeterol diskus, albuterol hydrofluoroalkane (HFA) inhaler, and montelukast presented to our clinic complaining of recurrent episodes of acute shortness of breath immediately following each administration of albuterol for 4 weeks. PFTs were performed with levalbuterol (Xopenex) and albuterol (ProAir), yielding significant decrease in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). Nebulized albuterol and ipratropium bromide also improved FEV1 and FVC. He was successfully transitioned to an ipratropium rescue inhaler for asthma exacerbations.
CONCLUSIONS: Paradoxical bronchoconstriction is the unexpected constriction of smooth muscle walls of the bronchi that occurs in the setting of an expected bronchodilatory response. This phenomenon has been observed with β₂-agonist-containing inhaler formulations and is an under-recognized adverse event. Theories suggest that the formulation excipients can trigger airway hyperresponsiveness in patients with allergically inflamed airways. Removal of excipients or use of anticholinergic inhalers improved respiratory function. Clinicians should be aware of paradoxical bronchospasm as an adverse effect with common inhaler formulations containing β₂-agonists and counsel patients accordingly in the appropriate clinical setting.
Keywords: airway remodeling, Albuterol, Anti-Asthmatic Agents
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947938
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947163
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949194
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948731
Most Viewed Current Articles
21 Jun 2024 : Case report
101,839
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
54,458
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
38,088
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,936
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200